22q11.2 microdeletion and increased risk for type 2 diabetes

Autor: Erik Boot, Andrea Tyrer, Lily Van, Tracy Heung, Christian Fenn, Anne S. Bassett, Eva W.C. Chow, Sarah L. Malecki, Marcos Sanches, Maria Corral, Susan R. George, Satya Dash
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: EClinicalMedicine
EClinicalMedicine, Vol 26, Iss, Pp 100528-(2020)
ISSN: 2589-5370
Popis: Background: The 22q11.2 microdeletion is the pathogenic copy number variation (CNV) associated with 22q11.2 deletion syndrome (22q11.2DS, formerly known as DiGeorge syndrome). Familiar endocrinological manifestations include hypoparathyroidism and hypothyroidism, with recent elucidation of elevated risk for obesity in adults. In this study, we aimed to determine whether adults with 22q11.2DS have an increased risk of developing type 2 diabetes (T2D). Methods: We studied the effect of the 22q11.2 microdeletion on risk for T2D, defined by history and glycosylated hemoglobin (HbA1c), using weighted survey data from the adult Canadian population (based on n = 11,874) and from a clinical cohort of adults with 22q11.2DS (n = 314), aged 17–69 years. Binomial logistic regression models accounted for age, sex, non-European ethnicity, family history of T2D, obesity, and antipsychotic medication use. Findings: The 22q11.2 microdeletion was a significant independent risk factor for T2D (OR 2·44, 95% CI 1·39–4·31), accounting for other factors (p < 0·0001). All factors except sex were also significant within 22q11.2DS. The median age at diagnosis of T2D was significantly younger in 22q11.2DS than in the Canadian population sample (32 vs 50 years, p
Databáze: OpenAIRE